148 related articles for article (PubMed ID: 11436701)
21. Efficacy, tolerability, and pharmacokinetics of oxcarbazepine oral loading in patients with epilepsy.
Kim DW; Gu N; Jang IJ; Chu K; Yu KS; Cho JY; Yoon SH; Kim HS; Oh J; Lee SK
Epilepsia; 2012 Jan; 53(1):e9-12. PubMed ID: 22091603
[TBL] [Abstract][Full Text] [Related]
22. Oxcarbazepine: preclinical anticonvulsant profile and putative mechanisms of action.
Schmutz M; Brugger F; Gentsch C; McLean MJ; Olpe HR
Epilepsia; 1994; 35 Suppl 5():S47-50. PubMed ID: 8039471
[TBL] [Abstract][Full Text] [Related]
23. Plasma level monitoring of oxcarbazepine in epileptic patients.
González-Esquivel DF; Ortega-Gavilán M; Alcántara-López G; Jung-Cook H
Arch Med Res; 2000; 31(2):202-5. PubMed ID: 10880728
[TBL] [Abstract][Full Text] [Related]
24. Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy.
Wang Y; Zhang HN; Niu CH; Gao P; Chen YJ; Peng J; Liu MC; Xu H
Acta Pharmacol Sin; 2014 Oct; 35(10):1342-50. PubMed ID: 25220641
[TBL] [Abstract][Full Text] [Related]
25. Practical aspects of oxcarbazepine treatment.
Dam M
Epilepsia; 1994; 35 Suppl 3():S23-5. PubMed ID: 8156977
[TBL] [Abstract][Full Text] [Related]
26. Population pharmacokinetics of oxcarbazepine and its metabolite 10-hydroxycarbazepine in healthy subjects.
Antunes NJ; van Dijkman SC; Lanchote VL; Wichert-Ana L; Coelho EB; Alexandre Junior V; Takayanagui OM; Tozatto E; van Hasselt JGC; Della Pasqua O
Eur J Pharm Sci; 2017 Nov; 109S():S116-S123. PubMed ID: 28528287
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of oxcarbazepine and carbamazepine in human placenta.
Pienimäki P; Lampela E; Hakkola J; Arvela P; Raunio H; Vähäkangas K
Epilepsia; 1997 Mar; 38(3):309-16. PubMed ID: 9070593
[TBL] [Abstract][Full Text] [Related]
28. Relation of blood platelet count during carbamazepine and oxcarbazepine treatment with daily dose, and serum concentrations of carbamazepine, carbamazepine-10, 11-epoxide, and 10-hydroxycarbazepine.
Tutor-Crespo MJ; Hermida J; Tutor JC
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2007 Jun; 151(1):91-4. PubMed ID: 17690747
[TBL] [Abstract][Full Text] [Related]
29. Population pharmacokinetics of oxcarbazepine active metabolite in Chinese paediatric epilepsy patients and its application in individualised dosage regimens.
Lin WW; Li XW; Jiao Z; Zhang J; Rao X; Zeng DY; Lin XH; Wang CL
Eur J Clin Pharmacol; 2019 Mar; 75(3):381-392. PubMed ID: 30456415
[TBL] [Abstract][Full Text] [Related]
30. Impact of efflux transporters and of seizures on the pharmacokinetics of oxcarbazepine metabolite in the rat brain.
Clinckers R; Smolders I; Michotte Y; Ebinger G; Danhof M; Voskuyl RA; Della Pasqua O
Br J Pharmacol; 2008 Dec; 155(7):1127-38. PubMed ID: 18836479
[TBL] [Abstract][Full Text] [Related]
31. The regulation of serum sodium after replacing carbamazepine with oxcarbazepine.
Isojärvi JI; Huuskonen UE; Pakarinen AJ; Vuolteenaho O; Myllylä VV
Epilepsia; 2001 Jun; 42(6):741-5. PubMed ID: 11422328
[TBL] [Abstract][Full Text] [Related]
32. [Therapeutic drug monitoring of oxcarbazepine].
Bouquié R; Dailly E; Bentué-Ferrer D;
Therapie; 2010; 65(1):61-5. PubMed ID: 20205998
[TBL] [Abstract][Full Text] [Related]
33. The impact of age on lamotrigine and oxcarbazepine kinetics: a historical cohort study.
Wegner I; Wilhelm AJ; Sander JW; Lindhout D
Epilepsy Behav; 2013 Oct; 29(1):217-21. PubMed ID: 23995050
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine.
Flesch G; Czendlik C; Renard D; Lloyd P
Drug Metab Dispos; 2011 Jun; 39(6):1103-10. PubMed ID: 21389120
[TBL] [Abstract][Full Text] [Related]
35. Glomerular Filtration Rate Is a Major Predictor of Clearance of Oxcarbazepine Active Metabolite in Adult Chinese Epileptic Patients: A Population Pharmacokinetic Analysis.
Lin WW; Wang CL; Jiao Z; Yu XL; Zhang J; Zhang WB; Lin RF; Lin S; Lin XH
Ther Drug Monit; 2019 Oct; 41(5):665-673. PubMed ID: 31033858
[TBL] [Abstract][Full Text] [Related]
36. Oxcarbazepine pharmacokinetics and tolerability in children with inadequately controlled epilepsy.
Rey E; Bulteau C; Motte J; Tran A; Sturm Y; D'Souza J; Markabi S; Pons G; Dulac O
J Clin Pharmacol; 2004 Nov; 44(11):1290-300. PubMed ID: 15496647
[TBL] [Abstract][Full Text] [Related]
37. Effects of charcoal on the absorption and elimination of the antiepileptic drugs lamotrigine and oxcarbazepine.
Keränen T; Sorri A; Moilanen E; Ylitalo P
Arzneimittelforschung; 2010; 60(7):421-6. PubMed ID: 20712131
[TBL] [Abstract][Full Text] [Related]
38. Population pharmacokinetic model development and its relationship with adverse events of oxcarbazepine in adult patients with epilepsy.
Jang Y; Yoon S; Kim TJ; Lee S; Yu KS; Jang IJ; Chu K; Lee SK
Sci Rep; 2021 Mar; 11(1):6370. PubMed ID: 33737678
[TBL] [Abstract][Full Text] [Related]
39. Relationship between mono-hydroxy-carbazepine serum concentrations and adverse effects in patients on oxcarbazepine monotherapy.
Sattler A; Schaefer M; May TW
Seizure; 2015 Sep; 31():149-54. PubMed ID: 26362393
[TBL] [Abstract][Full Text] [Related]
40. Population pharmacokinetics of oxcarbazepine active metabolite in Chinese children with epilepsy.
Li X; Wei S; Wu H; Zhang Q; Zhao Z; Mei S; Feng W; Wu Y
Eur J Pediatr; 2023 Oct; 182(10):4509-4521. PubMed ID: 37493972
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
